NATsIONAL'NYE REKOMENDATsII PO OPREDELENIYu RISKA I PROFILAKTIKE VNEZAPNOY SERDEChNOY SMERTI

Cover Page

Abstract



НАЦИОНАЛЬНЫЕ РЕКОМЕНДАЦИИ ПО ОПРЕДЕЛЕНИЮ РИСКА И ПРОФИЛАКТИКЕ ВНЕЗАПНОЙ СЕРДЕЧНОЙ СМЕРТИ

Andrey Vyacheslavovich Ardashev

Evgeniy Vladimirovich Shlyakhto

Grigoriy Pavlovich Arutyunov

Yuriy Nikitich Belenkov

  1. Бойцов С.А., Никулина Н.Н., Якушин С.С. и др. Внезапная сердечная смерть у больных ИБС: распространенность, выявляемость и проблемы статистического учета. Российский кардиологический журнал 2011; 2:59-64.
  2. Центральная база статистических данных Федеральной службы государственной статистики, 2010 год (www.gks.ru/dbscripts/Cbsd)
  3. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98:2334-2351
  4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:1064 - 1108.
  5. Priori SG, Aliot E, Blømstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations. Eur Heart J 2001; 22:1374–450
  6. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159
  7. Leclercq JF, Coumel P, Maison-Blanche P, et al. [Mechanisms determining sudden death. A cooperative study of 69 cases recorded using the Holter method]. Arch Mal Coeur Vaiss. 1986; 79(7):1024-33.
  8. Panidis IP, Morganroth J. Sudden death in hospitalized patients: cardiac rhythm disturbances detected by ambulatory electrocardiographic monitoring. J Am Coll Cardiol. 1983;2(5):798-805.
  9. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 1997;96:3215-3223
  10. Roger VL, Go A, Lloyd-Jones DM, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association Circulation 2012; 125:e2-e220
  11. Gillum RF. Sudden death in the United States: 1980–1985. Circulation 1989; 79:756–765.
  12. Бокерия Л.А., Ревишвили А.Ш., Неминущий Н.М. Внезапная сердечная смерть. – М.: ГЭОТАР-медиа, 2011. – 272 с.
  13. Мазур Н.А. Популяционные исследования и их значение в изучении эффективности первичной и вторичной профилактики ишемической болезни сердца среди населения. Кардиология. 1977; 17 (8): 5-9.
  14. Мазур Н.А., Никитин Ю.П., Гафаров В.В. Результаты двухлетнего эпидемиологического изучения инфаркта миокарда в Новосибирске. Тер. архив. 1981; 8: 10-3.
  15. Банщиков Г.Т., Т.Н. Зиновенко, Г.Я. Гудков. Внезапная добольничная смерть от острой коронарной недостаточности и инфаркта миокарда (по данным регистра острого инфаркта миокарда в Вологде). Кардиология 1985; 4: 103-4.
  16. Якушин С.С., Бойцов С.А., Фурменко Г.И., и др. Внезапная сердечная смерть у больных ишемической болезнью сердца по результатам Российского многоцЕнтрового эпидемиологического исследования Заболеваемости, смертности, кАчества диагностики и лечения острых форм ИБС (РЕЗОНАНС). Российский кардиологический журнал. 2011; 2: 59-64.
  17. Солохин Ю.А., Макаров Л.М., Комолятова В.Н. Внезапная внегоспитальная сердечная смерть в молодом возрасте (анализ за 5 лет по данным 2-го танатологического отделения бюро Судебно- медицинской экспертизы Департамента Здравоохранения г. Москвы) "Медицинская экспертиза и право" (2012 г., в печати).
  18. Внезапная сердечная смерть. Рекомендации Европейского кардиологического общества (ред. проф. Н.А. Мазур). – М: Медпрактика-М, - 2003.- 148 с.
  19. Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time- dependence of risk.Circulation 1992; 85: 12-20.
  20. Vreede-Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I. et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500-5.
  21. Sans S., Kesteloot H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task force of the European society of cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J 1997; 18: 1231-48.
  22. Myerburg R.J. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol 2001; 12: 369-81.
  23. Zheng Z.J., Croft J.B., Giles W.H. et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104: 2158-63.
  24. Bigger JT Jr. Identification of patients at high risk for sudden cardiac death. Am J Cardiol. 1984; 54(9):3D-8D.
  25. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997;337(22):1576-83.
  26. Connolly S., Gent M., Roberts R., et al. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable defibrillator against amiodarone. Circulation 2000; 101(11):1297-302.
  27. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. Circulation 2000;102:748–754
  28. Camm AJ, Julian D, Janse G, et al. The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators. Am J Cardiol 1993; 72(16):95F-98F.
  29. Cairns JA, Connolly SJ, Roberts R, Gent M. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators. Am J Cardiol. 1993; 72(16):87F-94F.
  30. Olesen RM, Thomsen PE, Saermark K, Glikson M, et al. Statistical analysis of the DIAMOND MI study by the multipole method. J Physiol Meas 2005; 26(5):591-8.
  31. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med, 1996; 335:1933–1940.
  32. Moss AJ, Zareba W, Hall WJ et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002; 346:877–883.
  33. Buxton AE, Lee KL, Fisher JD et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.N Engl J Med, 1999; 341: 1882–1890
  34. Bardy GH, Lee KL, Mark DB et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005; 352: 225–237.
  35. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002;347:878–885.
  36. Colman N, Nahm K, Ganzeboom KS, et al. Epidemiology of reflex syncope. Clin Auton Res 2004;14 (Suppl 1):i9–i17.
  37. Milstein S, Buetikofer J, Lesser J, et al. Cardiac asystole: a manifestation of neutrally mediated hypotension bradycardia. J Am Coll Cardiol 1989;14:1626–1632.
  38. Almquist A, Gornick CC, Benson DW, et al. Carotid sinus hypersensitivity: evaluation of the vasodepressor component. Ciculation 1985;67:927–936.
  39. Ungar A, Del Rosso A, Giada F, et al. Earle and late outcome of treated patients referred for syncope to emergency department: the EGSYS 2 follow-up study. Eur Heart J 2010;32:2021–2026.
  40. Weijenberg MP, Feskens EJ, Kromhout D. Blood pressure and isolated systolic hypertension and the risk of coronary heart disease and mortality in elderly men (the Zutphen Elderly Study). J Hypertens 1996;14:1159–66.
  41. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl 1991;9:S3–S8
  42. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454–9.
  43. Staessen JA, Wang JG, Thijs L, Fagard R. Overview of the outcome trials in older patients with isolated systolic hypertension. J Hum Hypertens 1999;13:859–63.
  44. Collins R, Peto R, Mac Mahon S et al. Blood pressure, stroke, and coronary heart disease. Part2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827–38.
  45. Cupples LA, Gagnon DR, Kannel WB. Long- and short-term risk of sudden coronary death. Circulation 1992;85:I11–I18.
  46. Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995; 91:1749–56.
  47. Sexton PT, Walsh J, Jamrozik K, Parsons R. Risk factors for sudden unexpected cardiac death in Tasmanianmen. Aust N Z J Med 1997;27:45–50.
  48. Shepherd J, Cobbe SM, FordI et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7.
  49. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615–22.
  50. National Cholesterol Education Program. Second Report of the Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1333–445.
  51. Albert CM, Hennekens CH, O’Donnell CJ et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279:23–8.
  52. Burke AP, Farb A, MalcomGT, et al. Plaque rupture and sudden death related to exertionin men with coronary artery disease. JAMA 1999; 281:921–6.
  53. Lemaitre RN, Siscovick DS, Raghunathan TE, et al. Leisure-time physical activity and the risk of primary cardiac arrest. Arch Intern Med 1999; 159:686–90.
  54. Aberg H, Lithell H, Selinus I, Hedstrand H. Alcohol in temperance and social disability as risk factors for different causes of death. Acta Med Scand 1986; 220:351–9.
  55. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 1993; 341:1423–8.
  56. Vreede-Swagemakers JJ, Gorgels AP, Weijenberg MP et al. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. J Clin Epidemiol 1999;52:601–7.
  57. Dekker JM, Schouten EG, Klootwijk P, et al. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. Am J Epidemiol 1997;145:899–908.
  58. Kannel WB, SchatzkinA. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985;5:141B–149B.
  59. Escobedo LG, Caspersen CJ. Risk factors for sudden coronary death in the United States. Epidemiology 1997;8:175–80.
  60. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986; 314:271–5.
  61. Curb JD, Rodriguez BL, Burchfiel CM, et al. Sudden death, impaired glucose tolerance , and diabetesin Japanese American men. Circulation 1995; 91:2591–5.
  62. Suhonen O, Reunanen A, Knekt P, Aromaa A. Risk factors for sudden and non-sudden coronary death. Acta Med Scand 1988;223:19–25.
  63. De Bacquer D, De Backer G, Kornitzer M, et al. Prognostic value of ischemic electrocardiographic findings for cardiovascular mortality in men and women. J Am Coll Cardiol 1998;32:680–5.
  64. Kors JA, de Bruyne MC, Hoes A, et al. T-loop morphology as a marker of cardiac events in the elderly. J Electrocardiol 1998;31(Suppl):54–9.
  65. Burton F, Cobbe SM. Dispersion of ventricular repolarization and refractoriness. Cardiovas Res 2001;50:10–23.
  66. Dekker JM, Schouten EG, Klootwijk P, et al. Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation1994;90:779–85.
  67. deBruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97:467–72.
  68. Manttari M, Oikarinen L, ManninenV, Viitasalo M. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population. Heart 1997;78:268–72.
  69. Fogoros R. Electrophysiologic Testing 4-th edition Wiley-Blackwell, p. 304
  70. Клинические рекомендации ВНОА по проведению клинических электрофизиологических исследований, катетерной (радиочастотной) абляции и имплантации кардиостимуляторов, кардиовертеров-дефибрилляторов у больных с нарушениями ритма сердца (2011 г.). «Золотой абрикос», 518 с.
  71. Dargie HJ. Effect CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-1390.
  72. Chadda K., Goldstein S., Byington R. et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503 – 510.
  73. Goldstein S., Fagerberg B., Hjalmarson A. et al. For the MERIT-HF Study Group. Metoprolol- controlled release/extended release in patient with severe heart failure. J. Am. Coll. Cardiol. 2001, 38: 932-938.
  74. Lechat Ph. The cardiac Insufficiency Bisoprolol Study – II (CIBIS - II): a randomised trial. Lancet 1999; 353: 9-13.
  75. Boutitie F. et al. Amiodarone Interaction With ß-Blockers. Analysis of the Merged EMIAT and CAMIAT Databases. Circulation 1999; 99:2268-2275.
  76. López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Task Force On Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25(15):1341-62.
  77. Yusuf S, Sleight P, Pogue J, et al. Effects of an Angiotensin-Converting Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patient. N Engl J Med 2000; 342: 145-153.
  78. Hertzel C.G. et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–259.
  79. Fox K.M. et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double – blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003; 362: 782-788.
  80. Domanski M.J., Exner D.V., Borkowf C.B., et al. Effect of Angiotensin-Converting Enzyme Inhibition on Sudden Cardiac Death in Patients Following Acute Myocardial Infarction. A Meta-Analysis of Randomized Clinical Trials. J Am Coll Cardiol 1999; 33:598-604.
  81. Pfeffer M. A. Braunwald E., Moye L. A. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Result of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 10:669- 677.
  82. Kober L., Torp-Pedersen C., Carlsen J. E. et al. For the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 1995; 333:1670-1676.
  83. Solomon S. D., Wang D., Finn P. et al. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients : The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110:2180-2183.
  84. Pitt B, Zannad F, Remme WJ, et al. Effectivnes of spironolactone added to an angiotensin-converting enzyme inhibitor and loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996; 78: 902-907.
  85. Pitt B., Remme W., Zannad F. et. Al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 384: 1309-1321.
  86. Pitt B., Zannad F., Remme W., et. Al. For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
  87. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению хронической сердечной недостаточности (третий пересмотр) 2009.
  88. Nicklas J.M., Pitt B., Timmis G. et. al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1999;325(5):293-302.
  89. Cholesterol Treatment Trialist Collaboratoz - Efficacy and Safety of Cholesterol –lowering Treatment: Prospective Meta-Analysis of Data 9056 Participants in 14 Randomised Trials of Statins. Lancet 2005; 366:1267-1277.
  90. Руководство по нарушениям ритма сердца / под ред. Е.И. Чазова, С.П. Голицына. — М.: ГЭОТАР-Медиа, 2010. — 416 с
  91. Арболишвили Г.Н., Мареев В.Ю. Возможности применения омега-3 полиненасыщенных жирных кислот для первичной профилактики у больных сердечной недостаточностью ишемической этиологии. Cердечная недостаточность 2008; 2:73-78.
  92. Громова О.А., Торшин И.Ю., Калачева А.Г., Грачева О.Н. Мировой опыт омега-3 ПНЖК. Крупномасштабные клинические исследования омега-3 ПНЖК: об эффективности, доказательности и перспективах. Сердце 2011; 5: 263-272
  93. Marchioli R., Barzi F., Bomba E., et al. Early Protection against Sudden Death by n-3 Polyunsaturated Fatty Acids after Myocardial Infarction: Time-Course Analysis of the Result of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) Prevenzione. Circulation 2002; 105: 1897-1903.
  94. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223-30.
  95. Нифонтов Е.М., Шихалиев Д.Р., Богачев М.И. и др. Антиаритмическая эффективность омега-3 полиненасыщенных жирных кислот у больных стабильной ишемической болезнью сердца с желудочковыми нарушениями ритма. Кардиология 2010; 12:15-17.
  96. Мазур Н.А. Омега-3 полиненасыщенные жирные кислоты: доказательства пользы и перспективы их применения. Кардиология 2012; 4: 80 - 84
  97. Царегородцев Д.А., Гавва Е.М., Сулимов В.А. Омега-3-полиненасыщенные жирные кислоты в лечении заболеваний сердечно-сосудистой системы. Кардиология 2010; 8:56 – 62
  98. Шляхто Е.В., Новикова И.В., Рудаков М.М., Трешкур Т.В. Желудочковые аритмии у больных ишемической болезнью сердца: современные концепции этиопатогенеза, диагностики и лечения. Вест. аритмологии 2002; 30: 72-75.
  99. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
  100. The Cardiac Arrhythmia Suppression Trial-II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction: the Cardiac Arrhythmia Suppression Trial-II. N Engl J Med. 1992;327:227-233.
  101. Гиляров М.Ю., Сулимов В.А. Амиодарон: прошлое, настоящее и будущее. Клиническая фармакология и терапия 2006;4: 60-65.
  102. Аmiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350:1417-1424.
  103. Gruberg L. et al. SCD-HeFT: Sudden Cardiac Death in Heart Failure Trial. Medscape Cardiology 2004; 16.
  104. Rossenbacker T., Priori S.G., Zipes D.P. The fight against sudden cardiac death: consensus guidelines as a reference. Eur. Heart J. Suppl., Dec. 2007; 9: I50 - I58.
  105. Al-Khatib S.M., Sanders G.D., Cicik A., et al. Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. Am H Jour 2008; 156:613-22.
  106. Aziz EF, Javed F, Pratap B, Herzog E. Strategies for the prevention and treatment of sudden cardiac death. Open Access Emerg Med. 2010; 2: 99-114.
  107. Christine M. Albert. Prediction of Sudden Cardiac Death in Patients With Coronary Heart Disease: The Challenge Ahead. Circ Cardiovasc Imaging 2008; 1:175-177.
  108. Mark Estes N,A. et al. The Challenge of Predicting and Preventing Sudden Cardiac Death Immediately After Myocardial Infarction. Circulation 2009; 120:185-187.
  109. Бокерия Л.А., Бокерия О.Л., Киртбая Л.Н. Сердечная недостаточность и внезапная сердечная смерть. Анналы аритмологии. 2009, 4: 7-20.
  110. Ардашев А.В., Джанджгава А.О., Желяков Е.Г. Постоянная электрокардиостимуляция и дефибрилляция в клинической практике. МЕДПРАКТИКА-М, 2007, 224 с.
  111. Spotnitz HM, Herre JM, Raza ST, et al. Effect of implantable cardioverter-defibrillator implantation on surgical morbidity in the CABG Patch Trial. Surgical Investigators of the Coronary Artery Bypass Graft Patch Trial. Circulation. 1998; 98(19 Suppl):II77-80.
  112. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453-8.
  113. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter- defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol. 2003; 41(10):1707-12.
  114. Kadish A, Quigg R, Schaechter A, Anderson et al. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing Clin Electrophysiol. 2000 Mar; 23(3):338-43.
  115. Hohnloser SH, Kuck KH, Dorian P, et al, Prophylactic use of an implantable cardioverter- defibrillator after acute myocardial infarction. DINAMIT Investigators. N Engl J Med. 2004; 351(24):2481-8.
  116. Ligang Ding, et al. The long-term effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28(1):42-51
  117. Cappato R, Smith WM, Hood MA, Crozier IG, Jordaens L, Spitzer SG, Ardashev AV, Boersma L, Lupo P, Grace AA, Bardy GH. Subcutaneous chronic implantable defibrillation systems in humans. J Interv Card Electrophysiol. 2012
  118. Bardy GH, Lee KL, Mark DB et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005; 352: 225–237.
  119. Everitt MD, Saarel EV. Use of the wearable external cardiac defibrillator in children. Pacing Clin Electrophysiol. 2010; 33(6):742-6.
  120. V. Tan, J. Yap, Li-Fern Hsu, R. Liew. Catheter ablation of ventricular fibrillation triggers and electrical storm. Europace. 2012
  121. Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. Tex Heart Inst J. 2011; 38(2):111-21.
  122. Proietti R, Sagone A. Electrical storm: Incidence, Prognosis and Therapy. Indian Pacing Electrophysiol J. 2011; 11(2):34-42.
  123. Mallidi J, Nadkarni G, Berger R, et al. Meta-Analysis of Catheter Ablation as an Adjunct to Medical Therapy for Treatment of Ventricular Tachycardia in Patients with Structural Heart Disease. Heart Rhythm 2011; 8(4):503–510.
  124. Ардашев А.В, Склярова Т.Ф., Шаваров А.А. и соавт. Особенности центральной гемодинамики у пациентов с идиопатическими нарушениями ритма из области выходного тракта правого желудочка до радиочастотной катетерной абляции и в течение года после нее. Кардиология 2009; 3:4-9
  125. Schwartz PJ, Stone HL. Left stellectomy in the prevention of ventricular fibrillation caused by acute myocardial ischemia in conscious dogs with anterior myocardial infarction. Circulation 1980; 62:1256–1265
  126. Clementy N, Pierre B, Lallemand B, et al. Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction. Europace 2012; 14(7):968-74
  127. Lee MS, Yang T, Dhoot J, Liao H. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention and drug-eluting stents in patients with unprotected left main coronary artery narrowings. Am J Cardiol. 2010; 105(8):1070-5.
  128. Kim YH, Park DW, Kim WJ, et al. Validation of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score for prediction of outcomes after unprotected left main coronary revascularization. JACC Cardiovasc Interv 2010; 3(6):612-23.
  129. Niccoli G, De Felice F, Belloni F, et al. Late (3 Years) Follow-Up of Successful Versus Unsuccessful Revascularization in Chronic Total Coronary Occlusions Treated by Drug Eluting Stent. Am J Cardiol. 2012 Jun 19. [Epub ahead of print]
  130. Pegg TJ, Selvanayagam JB, Jennifer J, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010; 12:56.
  131. Акчурин Р.С., Васюк Ю.А., Карпов Ю.А и соавт. Национальные рекомендации «Диагностика и лечение стабильной стенокардии». Кардиоваскулярная терапия и профилактика 2008; 7(6), Приложение 4
  132. Sarter B.H. Finkle J.K., Gerszten R.E. et al. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1999; 28:122-129.
  133. Болдуева С.А., Леонова И.А., Бурак Т.Я. и соавт. Фракция выброса и другие предикторы внезапной кардиальной смерти у больных, перенесших инфаркт миокарда. Журнал сердечная недостаточность 2008; 9(3):111-117.
  134. Болдуева С.А., Шабров А.В., Лебедев Д.С и соавт. Прогнозирование и профилактика внезапной кардиальной смерти у больных, перенесших инфаркт миокарда. Кардиоваскулярная терапия и профилактика 2008; 7(3):56-62.
  135. Uretsky B.F., Thygesen K., Daubert J.C. et al. Predictors of Mortality From Pump Failure and Sudden Cardiac Death in Patients With Systolic Heart Failure and Left Ventricular Dyssynchrony: Results of the CARE-HF Trial. Journal of Cardiac Failure 2008; 14 (8): 670-675.
  136. Tada T., Shiba N., Watanabe J. Prognostic value of anemia in predicting sudden death of patients with diastolic heart failure. International Journal of Cardiology 2008; 128: 419 – 421.
  137. Sabir I.N., Usher-Smith J.A., Huang C.L.H. Risk stratification for sudden cardiac death. Progress in Biophysics and Molecular Biology 2008; 98: 340 – 346.
  138. Cannizzaro L.A., Piccini J.P., Patel U.D. Device Therapy in Heart Failure Patients With Chronic Kidney Disease. J Am Coll Cardiol 2011; 58 (9): 889 – 96.
  139. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association; American College of Cardiology Foundation; Heart Rhythm Society. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation. 2008;118(14):1497-1518.
  140. Feruglio G, Rickards A, Steinbach K. Cardiac Pacing in the world: A survey of the state of the art in 1986. Pacing Clin Electrophysiol 1987; 10: 768–77.
  141. Shaw DB, Holman RR, Gowers I. Survival in sinoatrial disorder (sick-sinus syndrome). Br Med J 1980; 280: 139–41.
  142. Rosenqvist M, Brandt J, Schuller H. Long-term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J 1988; 116:16–22.
  143. McAnulty JH, Rahimtoola SH, Murphy E et al. Natural history of ‘high-risk’ bundle-branch block: final report of a prospective study. N Engl J Med 1982; 307: 137–43.
  144. Dhingra RC, Denes P, Wu D, Chuquimia R, Rosen KM. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block. Circulation 1974; 49: 638–46.
  145. Denes P, Dhingra RC, Wu D, et al. Sudden death in patients with chronic bifascicular block. Arch Intern Med 1977; 137: 1005–10.
  146. Peters RW, Scheinman MM, Modin C, et al. Prophylactic permanent pacemakers for patients with chronic bundle branch block. Am J Med 1979; 66: 978–85.
  147. Scheinman MM, Peters RW, Suave MJ et al. Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing. Am J Cardiol 1982;50: 1316–22.
  148. Scheinman MM, Weiss AN, Shafton E, Benowitz N, Rowland M. Electrophysiologic effects of procaine amide in patients with intraventricular conduction delay. Circulation 1974; 49: 522–9.
  149. Tonkin AM, Heddle WF, Tornos P. Intermittent atrioventricular block: procainamide administration as a provocative test. Aust N Z J Med 1978; 8: 594–602.
  150. Clemmensen P, Bates ER, Califf RM et al. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. Am J Cardiol 1991; 67: 225–30.
  151. Behar S, Zissman E, Zion M et al. Prognostic significance of second-degree atrioventricular block in inferior wall acute myocardial infarction. SPRINT Study Group. Am J Cardiol 1993; 72: 831–4.
  152. Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol 1992; 20: 533–40.
  153. Sholler GF, Walsh EP. Congenital complete heart block inpatients without anatomic cardiac defects. Am Heart J 1989; 118: 1193–8.
  154. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995; 92: 442–9.
  155. Michaelsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4: 85–101.
  156. Solti F, Szatmary L, Vecsey T, Renyi-Vamos F, Bodor E. Congenital complete heart block associated with QT prolongation. Eur Heart J 1992; 13: 1080–3.
  157. Silka MJ, Manwill JR, Kron J, McAnulty JH. Bradycardiamediated tachyarrhythmias in congenital heart disease and responses to chronic pacing at physiologic rates. Am J Cardiol 1990; 65: 488–93.
  158. Ardashev A, Makarenko A, Zhelyakov E, Shavarov A. Atrioventricular Nodal Reentrant Tachycardia Treatment using Novel Potential. Asian Cardiovasc Thorac Ann 2010;18:529-535
  159. Kappos KG, Kranidis AJ, Anthopoulos LP. Torsades de pointes following radiofrequency catheter His ablation. Int J Cardiol 1996; 57: 177–9.
  160. Satoh T, Zipes DP. Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs. Circulation 1996; 94:217–27.
  161. Zehender M, Buchner C, Meinertz T, Just H. Prevalence, circumstances, mechanisms, and risk stratification of sudden cardiac death in unipolar single-chamber ventricular pacing. Circulation 1992; 85: 596–605.
  162. Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006; 1: 27.
  163. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93 (5): 841–842.
  164. Coughlin S.S., Myers L., Michaels R.K. What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, Dilated Cardiomyopathy Study. J Natl Med Assoc 1997; 89: 277-282.
  165. Coughlin S.S., Neaton J.D., Sengupta A., Kuller L.H. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994; 139: 166-172.
  166. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564–1575.
  167. Di LA, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994; 72: S46–S51.
  168. Sugrue DD, Rodeheffer RJ, Codd MB, et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med 1992; 117: 117–123.
  169. Komajda M, Jais JP, Reeves F, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990;11:824–831.
  170. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473–82.
  171. P. Charron, M. Arad, E. Arbustini, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working group on Myocardial and Pericardial Diseases. Eur J Heart; 2010; 31: 2715-2728.
  172. Meune C, Van Berlo JH. Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 2006; 354: 209-210.
  173. van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005; 83(1): 79-83.
  174. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Circulation. 2011;124:2761-2796.
  175. Юзвинкевич С.А. Электрокардиотерапия гипертрофической кардиомиопатии. Клиническая аритмология, под ред. проф. Ардашева А.В. Медпрактика-М. М; 2009:532-547.
  176. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212– 2218.
  177. Elliott P.M., Gimeno Blanes J.R., Mahon N.G., et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophiccardiomyopathy. Lancet. 2001;357:420 – 424.
  178. Maron B.J., Semsarian C., Shen W.K., et al. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm. 2009;6:599 – 602.
  179. Elliott P.M., Gimeno J.R., Tome M.T., et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933–1941.
  180. Maron B.J. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J. 2010;74:2271–2282.
  181. Spirito P., Autore C., Rapezzi C., et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119:1703–1710.
  182. Maron B.J., Niimura H., Casey S.A. et al. Development of left ventricular hyperthrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutation. J Am Coll Cardiol. 2001; 38:315-321.
  183. Rosenzweig A., Watkins H., Hwang D.S. et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753-1760.
  184. Spada M., Pagliardini S., Yasuda M. et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
  185. Maron B.J., McKenna W.J., Danielson G.K. et al. ACC/ESC clinical experts consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;42:1687-1713.
  186. Oerger D.M., Picard M.H., Palacios I.F., et al. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97:1511– 1514.
  187. Ciampi Q., Betocchi S., Lombardi R., et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:278–284.
  188. Olivotto I., Maron B.J., Montereggi A., et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044–2051.
  189. Rubinshtein R., Glockner J.F., Ommen S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–58.
  190. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–412.
  191. Marcus F.I., McKenna W.J., Sherrill D. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Proposed modification of the Task Force Criteria. Circulation 2010; 121; 1533-1541
  192. Basso C., Corrado D., Marcus F.I. et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009; 373:1289-1300
  193. Norman M.W., McKenna W.J. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: perspectives on disease. Z Kardiol 1999; 88:550-554
  194. Nava A., Bauce B., Basso C., et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000; 36:2226-2233
  195. Azaouagh A., Churzidse S., Konorza T., Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol 2011;100:383-394
  196. Basso C., Corrado D., Thiene G. Cardiovascular causes of sudden death in young individuals including athletes. Cardiol Rev 1999; 7:127-135
  197. Гордеева М.В., Митрофанова Л.Б., Пахомов А.В. и др. Внезапная сердечная смерть молодых людей. Вест Аритм 2012; 68:27-37
  198. Яшин С.М., Думпис Я.Ю., Вайнштейн А.Б. Возможно ли поставить диагноз аритмогенной кардиомиопатии правого желудочка с помощью простого неинвазивного обследования, включающего ЭКГ диагностику и эхокардиографию? Вестник Аритмологии 2008; Приложение А: Программа и тезисы VIII Международного славянского конгресса по электростимуляции и клинической электрофизиологии сердца «Кардиостим»: 171
  199. Corrado D., Basso C., Thiene G. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment. Heart 2000; 83:588–595
  200. Gemayel C., Pelliccia A., Thompson P.D. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2001; 38:1773–81
  201. Fung W.H., Sanderson J.E. Clinical profile of arrhythmogenic right ventricular cardiomyopathy in Chinese patients. Int J Cardiol 2001; 81:9–18
  202. Ардашев А. Клиническая аритмология. М, Медпрактика-М, 2009 г.
  203. Кушаковский М.С. Аритмии сердца. СПб.: «Фолиант», 1998. – 640 с.
  204. Ардашев А.В, Рыбаченко МС., Желяков Е.Г. и соавт. Синдром Вольфа-Паркинсона-Уайта: классификация, клинические проявления, диагностика и лечение. Кардиология 2009; 10:84-94
  205. Rodriguez L-M, de Chillou C, Schlapfer J. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol 1992; 70:1213-1215.
  206. Klein GJ, Bashore TM, Sellers TD. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301:1080-1085.
  207. Timmermans C, Smeets JLRM, Rodriguerz LM. Aborted sudden death in the WPW syndrome. Am. J Cardiol 1995; 76: 492-494.
  208. Montoya PT, Brugada P, Smeets J. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J l991; A44-l50.
  209. Epstein A, Miles W, Garson Jr A. Personal and Public Safety Issues Related to Arrhythmias. That May Affect Consciousness: Implications for Regulation and Physician Recommendations. Circulation 1996; 94:1147-1166.
  210. Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff–Parkinson–White syndrome. N Engl J Med 2003; 349:1803-11.
  211. Yi-Jen Chen, Shih- Ann Chen, Ching-Tai Tai. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. JACC 1998; Vol. 32 No 3: p.732-738.
  212. Bromberg BI, Linsay BD, Cain ME. Impact of history and electrophysiologic charactetezation of accessory pathway on management strategies to reduce sudden death among children with WPW syndrom. JACC 1996; Vol. 27/ No 3:690-5.
  213. Wang Y, Scheinman MM, Chien WW. JC. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. JACC 1991; 18:1711–1719.
  214. Палеев Н.Р. Миокардиты. Болезни органов кровообращения: Руководство для врачей. Под ред. Е.И. Чазова. – М.: Медицина, 1997. – С. 543-561.
  215. Carniel E., Sinagra G., Bussani R. et al. Fatal myocarditis: morphologic and clinical features. Ital. Heart. J. 2004; 5 (9): 702-6.
  216. Kuhl U., Pauschinger M., Noutsias M. et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation. 2005; 111 (7): 887-93.
  217. Kyto V., Saraste A., Voipio-Pulkki L-M., Saukko P. Incidence of fatal myocarditis: a population- based study in Finland. Am. J. Epidem. 2007; 165 (5): 570-4.
  218. Арутюнов Г.П. Миокардиты (часть 1). Сердце. 2010; 9 (5): 297-306.
  219. Fabre A., Sheppard M.N. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006; 92 (3): 316-20.
  220. Maron B.J., Doerer J.J., Haas T.S. Sudden death in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006.Circulation. 2009; 119 (8): 1085-92.
  221. Towbin J.A., Lowe A.M., Colan S.D. et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children.JAMA. 2006; 296 (15): 1867-76.
  222. Hufnagel G., Pankuweit S., Richter A. et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). Herz. 2000; 25 (3): 279-85.
  223. Cooper L.T., Berry G.J., Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N. Engl. J. Med. 1997; 336 (26): 1860-6.
  224. Rassi A. Jn., Rassi A., Little W.C. Chaga’s heart disease. Clin. Cardiol. 2000; 23: 883-9.
  225. Гогин Е.Е., Тюрин В.П. Инфекционные эндокардиты // Диагностика и лечение внутренних болезней: Рук. для врачей / Под ред. Ф.И. Комарова.- М.: Медицина, 1996. - Т.1.- С.300-318.
  226. Тюрин В.П. Инфекционные эндокардиты: руководство / Под ред. акад. РАМН Ю.Л. Шевченко. - 2 е изд., доп. и перераб. - М. : ГЭОТАР Медиа, 2012. - 368 с. Nunley D.L., Perlman P.E. Endocarditis. Changing trends in epidemiology, clinical and microbiological spectrum. Postgrad. Med. 1993; 93:235-47.
  227. Murdoch D.R., Corey G.R., Hoen B. et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169: 463–73.
  228. Демин А.А., Скопин И.И., Соболева М.К. и др. Инфекционный эндокардит: новые стандарты диагностики и лечения. Клин. Медицина. 2003; 6: 68–71.
  229. Tleyjeh I.M., Abdel-Latif A., Rahbi H. et al. A systematic review of population-based studies of infective endocarditis. Chest. 2007; 132: 1025–35.
  230. Тюрин В.П. Современные подходы к терапии инфекционного эндокардита. Сердце. 2010; 9 (5): 307-12.
  231. San Roman J.A., Lopez J., Vilacosta I. et al. Prognostic stratification of patients with left-sided endocarditis determined at admission. Am. J. Med. 2007; 120: 369 e1–e7.
  232. Delahaye F., Alla F., Beguinot I. et al. In-hospital mortality of infective endocarditis: prognostic factors and evolution over an 8-year period. Scand. J. Infect. Dis. 2007; 39: 849–57.
  233. Mylonakis E., Calderwood S.B. Infective endocarditis in adults. N. Angl. J. Med. 2001; 345: 1318-30.
  234. Aguado J.M., Gonzalez-Vilchez F., Martin-Duran R. et al. Perivalvular abscess associated with endocarditis: clinical features and diagnostic accuracy of two-dimensional echocardiography. Chest 1993; 104: 88-93.
  235. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
  236. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
  237. Alberti K.G.M.M., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
  238. Рекомендации экспертов ВНОК по диагностике и лечению метаболического синдрома. Кардиоваскулярная терапия и профилактика 2009; №6, приложение №2.
  239. Чазова И.Е., Мычка В.Б. Метаболический синдром. Москва, Медиа Медика, 2004, 168 стр.
  240. Консенсус российских экспертов по проблеме метаболического синдрома: определение, диагностические критерии, первичная профилактика и лечение. Consilium Medicum 2010; 12 (№5): 5-11.
  241. Soydinc S., Davutoglu V., Akcay M. Uncomplicated metabolic syndrome is associated with prolonged electrocardiographic QTc interval and QTc dispersion. Ann Noninvasive Electrocardiol 2006; 11: 313-317.
  242. Paksoy F., Ulaş T., Bes C., et al. Corrected Qt interval in patients with metabolic syndrome. Dicle Med J 2011; 38: 274-277.
  243. Li W., Bai Y., Sun K., et al. Patients with Metabolic Syndrome Have Prolonged Corrected QT Interval (QTc). Clin Cardiol 2009; 32: E93–E99.
  244. Сапожникова И.Е., Тарловская Е.И., Тарловский А.К., Соболев А.А. Дисперсия интервалов Q-T И J-T у пациентов с артериальной гипертензией в сочетании с метаболическими нарушениями в рамках инсулинорезистентного синдромаОМА. Вестник аритмологии 2001; №24: 22-26.
  245. Рябыкина Г.В., Шишова Т.А., Лаптев Д.Н., и соавт. Динамика артериального давления, вариабельности ритма сердца и QTс у больных с метаболическим синдромом при лечении селективным бета-блокатором и бигуанидами. Системные гипертензии 2009; №3: 38-56.
  246. Park S.K., Schwartz J., Weisskopf M. et al. Low-Level Lead Exposure, Metabolic Syndrome, and Heart Rate Variability: The VA Normative Aging Study. Environ Health Perspect 2006; 114: 1718-1724.
  247. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability. Standards of Measurements, Physiological Interpretation, and Clinical Use. Circulation 1996; 93: 1043-1065.
  248. Koskinen T., Kähönen M., Jula A., et al. Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular risk in young Finns study. Diabet Med 2009; 26: 354-361.
  249. Min K.B., Min J.Y., Paek D., Cho S.I. The impact of the components of metabolic syndrome on heart rate variability: using the NCEP-ATP III and IDF definitions. Pacing Clin Electrophysiol. 2008; 31: 584-591.
  250. Liao D., Sloan R.P., Cascio W.E., et al. Multiple Metabolic Syndrome Is Associated With Lower Heart Rate Variability: The Atherosclerosis Risk in Communities Study. Diabetes Care 1998; 21: 2116- 2122.
  251. Невзоров В.А., Абрамов Е.А., Власенко А.Н. Особенности липидного спектра, вариабельности артериального давления и сердечного ритма у больных с клиническими проявлениями метаболического синдрома. Вестник аритмологии 2004; №36: 27-30.
  252. Аничков Д.А., Шостак Н.А., Котлярова Л.А., Иванов Д.С. Дисфункция вегетативной нервной системы у больных метаболическим синдромом: исследование вариабельности сердечного ритма. Кардиоваскул. тер. и профилактика 2005; 4 (4): 85-90.
  253. Кратнов А.Е., Климачева О.В., Третьяков С.В. Влияние факторов метаболического синдрома на изменение вариабельности ритма сердца. Современные технологии в медицине 2011; №3: 102-105.
  254. Хурс Е.М., Андреев П. В., Поддубная А. В., и соавт. Вегетативный дисбаланс в патогенезе метаболического синдрома. Клиническая медицина 2010; 88(6): 39-42.
  255. Минаков Э.В., Кудаева Л.А. Изучение особенностей формирования кардиальной нейропатии улиц с метаболическим синдромом и нарушением углеводного обмена (по данным анализа вариабельности сердечного ритма). Саратовский научно-медицинский журнал 2010; 6 (3): 582-585.
  256. Ferrara A.L., Vaccaro O., Cardoni O., et al. Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study. Nutr Metab Cardiovasc Dis 2003; 13: 126-132.
  257. Ferrara L.A., Cardoni O., Mancini M., Zanchetti A. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens 2007; 21: 795-801.
  258. Guerra F., Mancinelli L., Angelini L., et al. The Association of Left Ventricular Hypertrophy with Metabolic Syndrome is Dependent on Body Mass Index in Hypertensive Overweight or Obese Patients. PLoS One 2011; 6(1): e16630.
  259. Higham P.D., Adams P.C., Murray A., Campbell R.W. Plasma potassium, serum magnesium and ventricular fibrillation: a prospective study. Q J Med 1993; 86: 609-617.
  260. Marques J.L., George E., Peacey S.R., et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997; 14: 648-654.
  261. Heller S.R. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl 2002; 129: 27-32.
  262. Lattimore J.L., Celermajer D.S., Wilcox I. Obstructive sleep apnea and cardiovascular disease. JACC 2003; 41: 1429-1437.
  263. Vgontzas A.N., Bixler E.O., Chrousos G.P. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9:211-224.
  264. Somers V.K., White D.P., Amin R., et al. Sleep Apnea and Cardiovascular Disease An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. JACC 2008; 52; 686-717.
  265. Sharma S.K., Agrawal S., Damodaran D., et al. CPAP for the Metabolic Syndrome in Patients with Obstructive Sleep Apnea. N Engl J Med 2011; 365: 2277-2286.
  266. Drenick E.J. Fisler J.S. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg 1988: 155: 720-726.
  267. Sjostrom LV. Mortality of severely obese subjects. Am J Clin Nutt 1992:55:516S-23S.
  268. Bharati S., Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am Heart J 1995:129:273-81.
  269. Frank S., Colliver J.A., Frank A. The electrocardiogram in obesity: statistical analysis of 1,029 patients. JACC 1986; 7: 295-299.
  270. Alpert M.A., Terry B.E., Cohen M.V., et al. The electrocardiogram in morbid obesity. Am J Cardiol 2000: 85: 908-910.
  271. Mshui M.E., Saikawa T., Ito K., et al. QT interval and QT dispersion before and after diet therapy in patients with simple obesity. Proc Soc Exp Biol Med 1999; 220: 133-138.
  272. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225-236.
  273. Wong C., Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007; 4: 436-443.
  274. Mac Mahon S.W., Wilcken D.E., Macdonald G.J. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314: 334-339.
  275. Alpert M.A., Lambert C.R., Terry B.E., et al. Effect of weight loss on left ventricular mass in nonhypertensive morbidly obese patients. Am J Cardiol 1994; 73: 918-921.
  276. Carella M.J., Mantz S.L., Rovner D.R., et al. Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Int J Obes Relat Metab Disord 1996; 20: 938-942.
  277. Singh B.N., Gaarder T.D., Kanegae T., et al. Liquid protein diets and torsade de pointes. JAMA 1978; 240: 115-119.
  278. Doherty J.U., Wadden Т.А., Zuk L., et al. Long-term evaluation of cardiac function in obese patients treated with a very-low-calorie diet: a controlled clinical study of patients without underlying cardiac disease. Ain J Clin Nutr 1991; 53: 854-858.
  279. Fisler J.S. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr 1992; 56: 230S-234S.
  280. Surawicz B., Waller B.F. The enigma of sudden cardiac death related to dieting. Can J Cardiol 1995; 11: 228-231.
  281. Ahmed W., Flynn M.A., Alpert M.A. Cardiovascular complications of weight reduction diets. Am J Med Sci 2001; 321: 280-284.
  282. Neumarker K.J. Mortality and sudden death in anorexia nervosa. Int J Eat Disord 1997; 21: 205-212.
  283. Lupoglazoff J.M., Berkane N., Denjoy I., et al. Cardiac consequences of adolescent anorexia nervosa. Arch Mai Coeur Vaiss 2001; 94: 494-498.
  284. Isner J.M., Roberts W.C., Heymsfield S.B., et al. Anorexia nervosa and sudden death. Ann Intern Med 1985; 102: 49-52.
  285. Swenne I., Larsson P.T. Heait risk associated with weight loss in anorexia nervosa and eating disorders: lisk factors for QTc interval prolongation and dispersion. Acta Paediatr 1999; 88: 304-309.
  286. Brooks M.J., Melnik G. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy 1995; 15: 713-726.
  287. Schocken D.D., Holloway I.D., Powers P.S. Weight loss and the heart. Effects of anorexia nervosa and starvation. Arch Intern Med 19898 149: 877-881.
  288. Solomon S.M., Kirby D.F. The refeeding syndrome: a review. JPEN J Parenter Enteral Nutr 1990; 14: 90-97.
  289. Weinsier RL. Krumdieck CL. Death resulting from overzealous total parenteral nutrition: the refeeding syndrome revisited. Am J Clin Nutr 1981; 34: 393-399.
  290. Bray G.A., Bellanger T. Epidemiology, Trends, and Morbidities of Obesity and the Metabolic Syndrome. Endocrine 2006; 29: 109-117.
  291. Priori S. G., Aliot E., Blomstrom-Lundqvist C., et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-1450.
  292. Empana J-P., Duciemetiere P., Balkau B., Jouve X. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I. Eur Heart J 2007; 9: 1149-1154.
  293. Mulpuru S. K., Krummen D. E., Narayan S. M.: Sudden Death Risk in Type 2 Diabetic patients Post Myocardial Infarction: A “Sweet” Opportunity? Heart Rhythm. 2010; 7: 1404–1405
  294. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999;99:1978–83.
  295. Albert CM, Chae CU, Grodstein F, et al: Prospective study of sudden cardiac death among women in the United States. Circulation 2003;107:2096–2101
  296. Maffei P., Martini C., Milanesi A., et al: Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol 2005 , 30;104:197-203
  297. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al.: Arrhythmia profile in acromegaly. Eur Heart J, 1992; 13:51–56
  298. Weiss V, Sonka K, Pret lM, et al: Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 2000 23:515–519
  299. Arias M. A , Pachon M.; Rodriguez-Padial L.: Ventricular tachycardia in acromegaly Rev Port Cardiol 2011; 30: 223-226
  300. Herrmann BL, Bruch C, Saller B, Ferdin S, et al: Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol (Oxf) 2001; 55:201–207
  301. Alpert MA. Sudden cardiac arrest and sudden cardiac death on dialysis: Epidemiology, evaluation, treatment, and prevention. Hemodial Int. 2011;15 Suppl 1:S22-9.
  302. Drechsler C, Grootendorst DC, Pilz S et al. ,Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche DiabetesDialyseStudie). Am J Kidney Dis. 2011;58(4):599-607.
  303. Kanbay M, Solak Y, Covic A, Goldsmith D. Sudden cardiac death in patients with chronic kidney disease: prevention is the sine qua non. Kidney Blood Press Res. 2011;34(4):269-76.
  304. Pena, VS, Miravitlles, M, Gabriel, R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000;118,981-989
  305. Tálamo C, de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities Chest. 2007 Jan;131(1):60-7
  306. Краснова Ю.Н., Гримайлова Е.В., Дзизинский А.А., Черняк Б.А. Распространенность хронической обструктивной болезни легких в Иркутской области. Пульмонология 2006 №1б с. 98-
  307. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005;294:1255-1259
  308. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Update 2011. www.goldcopd.com
  309. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952–1959
  310. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118,656-65.
  311. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.
  312. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009 Mar;11(3):292-8
  313. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration medical system, 1991–1999. COPD 2005;2:35–41
  314. DeSilva RA. Central nervous system risk factors for sudden cardiac death Ann N Y Acad Sci 1982;382:143-161.
  315. Cox GF, Kunkel LM. Dystrophies and heart disease Curr Opin Cardiol 1997;12:329-343.
  316. Pelargonio G, Dello RA, Sanna T, et al. Myotonic dystrophy and the heart Heart 2002;88:665-670.
  317. Munoz J, Sanjuan R, Morell JS, et al. Ventricular tachycardia in Duchenne’s muscular dystrophy Int J Cardiol 1996;54:259-262.
  318. Samuels MA. Neurally induced cardiac damage. Definition of the problem Neurol Clin 1993;11:273-292.
  319. Merino JL, Peinado R. Arrhythmias associated with neuromuscular disorders Card Electrophysiol Rev 2002;6:132-135.
  320. Becane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation Pacing Clin Electrophysiol 2000;23:1661- 1666.
  321. Colleran JA, Hawley RJ, Pinnow EE, et al. Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy Am J Cardiol 1997;80:1494-1497.
  322. Corrado G, Lissoni A, Beretta S, et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy Am J Cardiol 2002;89:838-841.
  323. Ducceschi V, Nigro G, Sarubbi B, et al. Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy Int J Cardiol 1997;59:275-279.
  324. Perloff JK, Stevenson WG, Roberts NK, et al. Cardiac involvement in myotonic muscular dystrophy (Steinert’s disease)a prospective study of 25 patients. Am J Cardiol 1984;54:1074-1081.
  325. Hiromasa S, Ikeda T, Kubota K, et al. Myotonic dystrophyambulatory electrocardiogram, electrophysiologic study, and echocardiographic evaluation. Am Heart J 1987;113:1482-1488.
  326. Stevenson WG, Perloff JK, Weiss JN, et al. Facioscapulohumeral muscular dystrophyevidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292-299.
  327. James TN, Fisch C. Observations on the cardiovascular involvement in Friedreich’s ataxia Am Heart J 1963;66:164-175.
  328. Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases Am J Cardiol 1979;44:1396-1400.
  329. Charles R, Holt S, Kay JM, et al. Myocardial ultrastructure and the development of atrioventricular block in Kearns-Sayre syndrome Circulation 1981;63:214-219.
  330. James TN. Observations on the cardiovascular involvement, including the cardiac conduction system, in progressive muscular dystrophy Am Heart J 1962;63:48-56.
  331. Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994 Mar;35(3):326-30.
  332. Sansone V, Griggs RC, Meola G, et al. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol. 1997 Sep;42(3):305-12.
  333. Levitt LP, Rose LI, Dawson DM. Hypokalemic periodic paralysis with arrhythmia. N Engl J Med. 1972 Feb 3;286(5):253-4.
  334. Gutmann L. Periodic paralyses. Neurol Clin. 2000 Feb;18(1):195-202.
  335. Junker J, Haverkamp W, Schulze-Bahr E, et al. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. 2002 Aug 13;59(3):466.
  336. Bokenkamp R, Wilde AA, Schalij MJ, Blom NA. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen–Tawil syndrome. Heart Rhythm 2007;4:508–11.
  337. Pellizzon OA, Kalazich L, Ptacek LJ et al. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen–Tawil syndrome. J Cardiovasc Electrophysiol 2008;19:95–7.
  338. Макаров Л.М., Комолятова В.Н., Колосов В.О. и соавт. Синдром Андерсена-Тавила. Эффективность препаратов IC класса. Описание случая. Кардиология 2012 (в печати)
  339. Reichenbach, H., Meister, E. M., Theile, H. Herz-Hand-Syndrom: Eine neue Cariante mit Erregungsleitungsstorungen am Herzen und Syndaktylien einschleisslich ossarer Veranderungen an Handen und Fussen. Kinderarztl. Prax. 1992, 60: 54-56
  340. Marks, M. L., Trippel, D. L., Keating, M. T. Long QT syndrome associated with syndactyly identified in females. Am. J. Cardiol. 1995, 76: 744-745
  341. Splawski I., Timothy K., Sharpe L., et al. Ca (V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004,119: 19-31
  342. Tester D J., Ackerman M J. Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/Channelopathies in Clinical Practice. Circulation 2011;123:1021-1037.
  343. Westenskow P, Splawski I, Timothy KWet al. Compound Mutations. A Common Cause of Severe Long-QT yndrome. Circulation 2004;109:1834-41.
  344. Itoh H, Shimizu W, Hayashi K, et al. Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Heart Rhythm 2010;7:1411-8.
  345. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89–95,
  346. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866–1874.
  347. Калинин Л.А., Макаров Л.М., Чупрова С.Н., с соавт. Диагностические возможности тестов с физической нагрузкой при синдроме удлиненного интервала QT. Вестник аритмологии. 2001; 23:28-31
  348. Ревишвили А.Ш., Проничева И.В., Заклязьминская Е.В. с соавт. Опыт применения методов днк-диагностики в лечении больных с синдромом удлиненного интервала QT. Вестник аритмологии 2005; 42:35-43
  349. Moss A, Goldenberg I. Importance of Knowing the Genotype and the Specific Mutation When Managing Patients With Long-QT. Syndrome. Circ Arrhythmia Electrophysiol 2008;1;219-226
  350. Nannenberg, E. A., Sijbrands, E. J. G., Dijksman, et al. Mortality of Inherited Arrhythmia Syndromes / Clinical Perspective. Circulation: Cardiovascular Genetics 2012; 5(2):183-189.
  351. Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc. 1999; 74:1088 –1094.
  352. Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol. 1999;33:327–332.
  353. Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol. 1999; 84:876–879.
  354. Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1:60–64.
  355. Национальные рекомендации по допуску спортсменов с отклонениями со стороны сердечно-сосудистой системы к тренировочно-соревновательному процессу. Рац. Фарм. Кардиол. 2011; 7 (приложение №6)
  356. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol 2008; 51:2291–2300.
  357. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007;116:1137–1144.
  358. Ruan Y, Denegri M, Liu N, et al. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. Circ Res 2010;106:1374–1383.
  359. Shimizu W. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ J. 2008;72:1926 –1936.
  360. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292: 1341–1344
  361. AK Bhandari, MM Scheinman, F Morady, et al. Efficacy of left cardiac sympathectomy in the treatment of patients with the long QT syndrome. Circulation, 1984; 70: 1018 - 1023.
  362. Gollob M, Redpath C, Roberts J. "The Short QT syndrome: Proposed Diagnostic Criteria". J Am Coll Cardiol 2011; 57 (7):802–812
  363. Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: Pharmacological Treatment. J Am Coll Cardiol 2004; 43:1494–9
  364. Schimpf R, Wolpert C, Bianchi F, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol 2003;14(12):1273-7.
  365. Дупляков Д.В., Глухова В.Л., Максимова С.В и соавт. Частота регистрации ЭКГ-признаков синдрома Бругада. Кардиология 2007;47:55-9.
  366. Brugada R, Campuzano O, Brugada P, et al. Brugada Syndrome. 2005 Mar 31 [Updated 2012 Jan In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. http://www.ncbi.nlm.nih.gov/books/NBK1517/
  367. Заклязьминская Е.В. Проничева И.В, Ревишвили А.Ш. и соавт. Молекулярно- генетические основы синдрома Бругада. Анналы аритмологии №2, Первый Всероссийский съезд аритмологов, приложение. Июнь, 2005, с.81
  368. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndromeinsights for risk stratification and management. Circulation 2002;105:1342-1347
  369. Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm. 2009 Mar;6(3):341-8.
  370. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 –74.
  371. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res.2011;108:871–83.
  372. Napolitano C, Priori SG, Bloise R. Catecholaminergic Polymorphic Ventricular Tachycardia. 2004 Oct 14 [Updated 2012 Feb 16]. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. http://www.ncbi.nlm.nih.gov/books/NBK1289/
  373. Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A. 2004; 101: 9137–42.
  374. Дупляков Д.В., Емельяненко В.М. Cиндром ранней реполяризации желудочков. Кардиология 1998;5:64-67.
  375. Klatsky AL, Oehm R, Cooper RA, et al. The early repolarization normal variant electrocardiogram: correlates and consequences. Am J Med. 2003;115(3):171-7.
  376. Haissaguerre M, Derval N, Sacher F et al. Sudden Cardiac Arrest Associated with Early Repolarization N Engl J Med 2008;358:2016-2022
  377. Rosso R, Kogan E, Belhassen B et al. J-Point Elevation in Survivors of Primary Ventricular Fibrillation and Matched Control Subjects. Incidence and Clinical Significance J Am Coll Cardiol 2008;52:1231–8
  378. Tikkanen JT, Anttonen O, Junttila M. J. et al. Long-Term Outcome Associated with Early Repolarization on Electrocardiography. N Engl J Med 2009;361 2529-37.
  379. Moritz F. Sinner1., Wibke Reinhard2., et al. Association of Early Repolarization Pattern on ECG with Risk of Cardiac and All-Cause Mortality: A Population-Based Prospective Cohort Study (MONICA/KORA) PLoS Med. 2010;7(7):e1000314.
  380. Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm. 2010;7(4):549-58.
  381. Guilleminault C., Van Den Hoed J., Mitler M.M. In: Sleep apnea syndrome, ed by Guilleminault C., Dement W.C., Alain R. Liss., New York, 1978, P. 1.
  382. Block A.J., Boysen P.G., Wynne J.W., Hunt L.A. Sleep apnea, hypopnea, and oxygen desaturation in normal subjects. N Engl J Med 1979; 300:513-517.
  383. Белов А.М. Анализ процесса сна при полисомнографии. М.: Изд-во ТГТПС, 2000. 81с.
  384. Loube DI, Gay PC, Strohl KP, et al. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients. Chest 1999:115:863-66.
  385. Калинкин А.Л. Синдром обструктивного апноэ сна – фактор риска артериальной гипертонии. Артериальная гипертензия 2003; 2:37-41.
  386. Schafer H, Koehler U, Ploch T, Peter JH. Sleep-related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 1997;111:387-93.
  387. Shepard JW Jr, Garrison MW, Grither DA, Dolan GF. Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive sleep apnea. Chest 1985;88:335-40.
  388. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol 1983; 52:490-4.
  389. Fichter J, Bauer D, Arampatzis S et al. Sleep-related breathing disorders are associated with ventricular arrhythmias in patients with an implantable cardioverter-defibrillator. Chest 2002;122: 558-61.
  390. Rossi VA, Stoewhas AC, Camen G, et al. The effects of continuous positive airway pressure therapy withdrawal on cardiac repolarization: data from a randomized controlled trial. Eur Heart J 2012; doi: 10.1093/eurheartj/ehs073
  391. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005;352(12):1206-14.
  392. Хаютин В.М., Майков Е.Б., Мазыгула Е.П., и соавт. Полная поперечная блокада сердца во время ночного апноэ. Оценка состояния нервной регуляции сердца методом спектрального анализа. Кардиология 1998; 12
  393. Свиряев Ю.В., Звартау Н.Э., Ротарь О.П., и соавт. Использования CPAP-терапии на фоне медикаментозного лечения артериальной гипертензии у больных с синдромом апноэ во сне Артериальная гипертензия 2008; 14 (3):264-269
  394. Abe H, Takahashi M, Yaegashi H, et al. Efficacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients. Heart Vessels 2010; 25(1):63-9.
  395. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005;127(6):2076-84.
  396. Александрова C. А. Магнитнорезонансная томография с отсроченным конрастированием у пациентов с желудочковыми аритмиями. Бюллетень НЦССХ им. А.Н.Бакулева РАМН. 2011; 12 (6):223.
  397. Александрова С.А., Юрпольская Л.А., Макаренко В.Н. МР-диагностика некоронарогенной патологии миокарда у детей. Сердечно-сосудистые заболевания. 2011; 3:81-88
  398. Благова О. В., Недоступ А. В., Коган Е. А. и соавт. «Идиопатические» аритмии как симптом латентной болезни сердца: опыт постановки нозологического диагноза с помощью эндомиокардиальной биопсии. Кардиология и сердечно-сосудистая хирургия 2010; 1:24 – 32.
  399. Лебедев Д. С. , Татарский Р. Б. Аритмогенная дисплазия правого желудочка и роль вирусной инфекции: возможное сочетание и роль в патогенезе желудочковых аритмий. Вестник Аритмологии 2010; 58:15–20.
  400. Лебедев Д. С., Татарский Р. Б. и соавт. К вопросу об этиологии идиопатических желудочковых тахиаритмий – роль кардиотропных вирусов. Тезисы доклада на IV Всероссийском съезде аритмологов, 2011 г., стр. 68
  401. Носкова М. В. Этиология, топическая диагностика и результаты радиочастотной аблации некоронарогенных желудочковых аритмий. Дисс. на соискание степени канд. мед. наук, Москва, 2004
  402. Yusuf S, Hawken S, Ounpuu S, et al. Effect Of Potentially Modifiable Risk Factors Associated With Myocardial Infarction In 52 Countries (The INTERHEART Study): Case-Control Study. Lancet 2004;364:937-52.
  403. U.S. Department Of Health And Human Services. The Health Benefits Of Smoking Cessation: A Report Of The Surgeon General, DHHS Publication No. (CDC) 90-8416. Rockville, MD: U.S. Department Of Health And Human Services, Public Health Service, Centers For Disease Control And Prevention, 1990.
  404. Pope CA 3rd, Eatough DJ, Gold DR, et al. Acute Exposure To Environmental Tobacco Smoke And Heart Rate Variability. Environ Health Perspect 2001;109:711-6
  405. Stein PK, Rottman JN, Kleiger RE. Effect Of 21 Mg Transdermal Nicotine Patches And Smoking Cessation On Heart Rate Variability. Am J Cardiol 1996;77:701-5
  406. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003;107:2096–101.
  407. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986;314:271–5.
  408. Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect? Am J Cardiovasc Drugs. 2010;10(3):155-64.
  409. Levantesi G, Scarano M, Marfisi R, et al. Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol. 2007;100(11):1644-50.
  410. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7.
  411. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
  412. Aarsetoey H, Aarsetoey R, Lindner T, Staines H, Harris WS, Nilsen DW. Low levels of the omega-3 index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids. 2011;46(2):151-61.
  413. Pottala JV, Garg S, Cohen BE, et al. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the Heart and Soul study. Circ Cardiovasc Qual Outcomes. 2010 Jul;3(4):406-12.
  414. De Caterina R. n–3 Fatty Acids in Cardiovascular Disease. N Engl J Med 2011;364:2439-50.
  415. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 1994;91:9886-90.
  416. Billman GE, Kang JX, Leaf A. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids 1997;32:1161-8.
  417. Zhao YT, Chen Q, Sun YX, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann Med. 2009;41(4):301-10
  418. Corrado D., Basso C., Pavei A. et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA. 2006; 296 (13): 1593-601.
  419. Chevalier L. Sudden unexpected death in young athletes: reconsidering „hypertrophic cardiomyopathy“. Eur. J. Cardiovasc. Prev. Rehabil. 2009; 3: 23.
  420. Maron B.J., Doerer J.J., Haas T.S. et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119 (8): 1085-92.
  421. Suarez-Mier M.P., Aguilera B. Causas de muerte subita asociada al. deporte en Espana. Rev. Esp. Cardiol. 2002; 55(4): 347-58.
  422. Van Camp S.P., Bloor C.M., Mueller F.O. et al. Nontraumatic sports death in high school and college athletes. Med. Sci. Sports Exerc. 1995; 27: 641-7.
  423. Liberthson R.R. Sudden death from cardiac causes in children and young adults. N Engl J Med. 1996; 334: 1039-44.
  424. Земцовский Э.В. Спортивная кардиология. Гиппократ. 1995. 446с.
  425. Corrado D, Basso C., Schiavon M. et al. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death. J. Am. Coll. Cardiol. 2008; 52: 1981-9.
  426. Макаров Л.М., Солохин Ю.А. Внезапная внебольничная сердечная смерть у детей, подростков и лиц до 45 лет. Кардиология 2009;11:33-38.
  427. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002; 288 (23): 3008-13.
  428. Delise1 P, AlloccaG, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach Euro Heart J 2011;32,169–176
  429. Christiaans I, van Engelen K, van Langen I, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers Europace (2010) 12, 313–321.
  430. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of Hypertrophic Cardiomyopathy – Related Death Revisited in a Large Non–Referral-Based Patient Population. Circulation 2000;102:858-864.
  431. Monnig G, Eckardt L, Wedekind E, et al. Electrocardiographic risk stratification in families with congenital long QT syndrome. Euro Heart J 2006;27:2074–2080
  432. Gollob M, Hamilton R, Hershberger RE, et al; Heart Rhythm Society (HRS); European Heart Rhythm Association (EHRA). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).Europace. 2011;13(8):1077-109.
  433. Kannel WB, Cupples LA, D’Agostino RB. Sudden death risk in overt coronary heart diseasethe Framingham Study. Am Heart J 1987;113:799-804.
  434. Kuller L, Lilienfeld A, Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease Circulation 1966;34:1056-1068.
  435. Aronow WS. Treatment of ventricular arrhythmias in older adults J Am Geriatr Soc 1995;43:688-695.
  436. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population detection by 24-hour ambulatory electrocardiography. Chest 1982;81:302-307.
  437. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmiasefficacy and safety. Clin Cardiol 1997;20:372-377
  438. Aronow WS, Ahn C, Mercando AD, et al. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease J Gerontol A Biol Sci Med Sci 2002; 57:M178-M180.
  439. Geelen P, Lorga FA, Primo J, et al. Experience with implantable cardioverter defibrillator therapy in elderly patients Eur Heart J 1997;18:1339-1342.
  440. Panotopoulos PT, Axtell K, Anderson AJ, et al. Efficacy of the implantable cardioverter- defibrillator in the elderly J Am Coll Cardiol 1997;29:556-560.
  441. Saksena S, Mathew P, Giorgberidze I, et al. Implantable defibrillator therapy for the elderly Am J Geriatr Cardiol 1998;7:11-13.

Views

Abstract - 169

PDF (Russian) - 128

Cited-By


PlumX


Copyright (c) 2012 Ardashev A.V., Shlyakhto E.V., Arutyunov G.P., Belenkov Y.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies